Infinity Licenses Intellikine’s Oral PI3K Therapies for Oncology and Inflammatory Diseases

doi:10.3833/pdr.v2010i7.1372

Pharma Deals Review, Vol 2010, No 7 (2010)

Infinity Licenses Intellikine’s Oral PI3K Therapies for Oncology and Inflammatory Diseases

Heather Cartwright

Abstract

Infinity Pharmaceuticals has in-licensed global rights to Intellikine’s portfolio of phosphoinositide 3-kinase (PI3K) inhibitors for inflammatory diseases and oncology indications in a US$488.5 M deal.

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.